New antibiotic and method for developing it exploits microbes' natural environment
the ONA take:
Researchers have discovered a powerful new antibiotic, teixobactin, using an unusual method. Teixobactin was tested in mice and easily cured severe infections, with no side effects.
Testing in humans will not begin for approximately 2 years, according to the researchers; therefore, its safety and effectiveness are not known at this time.
Even if the drug passes all the tests, it may not be available for 5 or 6 years. Importantly, the researchers are excited about the method used to produce this antibiotic because it has the potential to lead to the discovery of more natural compounds to fight infections and cancer.
In this method, drugs are extracted from bacteria that live in dirt. The method exploits the biological antibiotics found in the natural environment—the dirt—where microbes exist.
The process involves diluting a soil sample and placing it on a specialized device. The device is then placed into a box full of the same soil the sample came from, thereby tricking the bacteria into growing into a colony in its natural environment. The method may help resolve two significant issues in global health: the increase in infections that resist commonly used drugs and the lack of new antibiotics to replace those that are no longer effective.
Researchers have discovered a powerful new antibiotic, teixobactin, using an unusual method.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|